Indication
Erdheim-Chester disease with BRAF V600 mutation
Erdheim-Chester disease with BRAF V600 mutation is a rare, clonal non-Langerhans cell histiocytic neoplasm driven by an activating oncogenic mutation in the BRAF gene, most frequently the BRAF V600E substitution. Read more about Erdheim-Chester disease with BRAF V600 mutation
0 drugs 0 manufacturers
Drugs that treat it
Common Erdheim-Chester disease with BRAF V600 mutation therapies.
No drugs are available
This indication does not currently contain public drugs.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonErdheim-Chester disease with BRAF V600 mutation is a rare, clonal non-Langerhans cell histiocytic neoplasm driven by an activating oncogenic mutation in the BRAF gene, most frequently the BRAF V600E substitution.
Primarily affecting middle-aged and older adults, this multisystem disease is characterized by the uncontrolled accumulation and infiltration of foamy, lipid-laden macrophages and accompanying fibrosis across diverse organ systems.
Common manifestations include bilateral, symmetric osteosclerosis of long bones, retroperitoneal fibrosis, perinephric infiltration, cardiovascular encasement, central diabetes insipidus, and neurological deficits.
Presence of the BRAF V600 mutation causes constitutive activation of the intracellular MAPK/ERK signaling pathway, driving cellular proliferation, tissue inflammation, and end-organ dysfunction.
- ashpublications.org
Erdheim-Chester disease with BRAF V600 mutation is a rare, clonal non-Langerhans cell histiocytic neoplasm driven by an activating oncogenic mutation in the BRAF gene, most frequently the BRAF V600E substitution
- nih.gov
Erdheim-Chester disease with BRAF V600 mutation is a rare, clonal non-Langerhans cell histiocytic neoplasm driven by an activating oncogenic mutation in the BRAF gene, most frequently the BRAF V600E substitution
- nih.gov
Erdheim-Chester disease with BRAF V600 mutation is a rare, clonal non-Langerhans cell histiocytic neoplasm driven by an activating oncogenic mutation in the BRAF gene, most frequently the BRAF V600E substitution Primarily affecting middle-aged and older adults, this multisystem disease is characterized by the uncontrolled accumulation and infiltration of foamy, lipid-laden macrophages and accompanying fibrosis across diverse organ systems Common manifestations include bilateral, symmetric osteos...
- oncotarget.com
Primarily affecting middle-aged and older adults, this multisystem disease is characterized by the uncontrolled accumulation and infiltration of foamy, lipid-laden macrophages and accompanying fibrosis across diverse organ systems Presence of the BRAF V600 mutation causes constitutive activation of the intracellular MAPK/ERK signaling pathway, driving cellular proliferation, tissue inflammation, and end-organ dysfunction
Personalize your experience
Follow Erdheim-Chester disease with BRAF V600 mutation and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.